Transfusion-associated graft versus host disease (TAGVHD)

Status: 
Ready to upload
Record number: 
1281
Adverse Occurrence type: 
Graft versus host disease
MPHO Type: 
Platelets
Estimated frequency: 
Case report. Patient with systemic lupus erythematosus treated with fludarabine.
Time to detection: 
10 days
Alerting signals, symptoms, evidence of occurrence: 
Fever, skin rash, pancytopenia, increased bilirubin, abnormal liver function tests.
Demonstration of imputability or root cause: 
Marrow biopsy showed severe aplasia and skin biopsy was consistent with GVHD. Allele-level HLA typing on circulating lymphocytes revealed extra HLA alleles not present in patient's pretreatment sample, but identical to the HLA haplotypes of an unrelated platelet donor. Non-leukocyte reduced, non-irradiated platelet from donor who was a previous platelet transfusion donor (90 days previously).
Imputability grade: 
3 Definite/Certain/Proven
Groups audience: 
Clinical complications
Keywords: 
fever
skin rash
pancytopenia
elevated liver enzymes
bilirubin elevation
HLA markers
apheresis platelets
non leukoreduced
non irradiated
TAGVHD (transfusion associated graft versus host disease)
platelets
fludarabine
SLE (systemic lupus erythematosus)
References: 
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus.
Suggest new keywords: 
Non-leukocyte reduced
Reference attachment: 
PDF icon * TAGVHD, Leitman, 2003.pdf
Suggest references: 
Leitman S.F., Tisdale, J.F., Bolan, C.D., Popovshky, M.A., Liippel, J.H., Balow, J.E., Boumpas, D.T. and Illei, G.G. (2003). Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 43(12):1667-71.